Ultime notizie per XPeng (NYSE:XPEV) Azioni

XPeng

Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.

Business,People,And,Humanoid,Ai,Robot,Sitting,And,Waiting,For

Equities

News

Markets

AMZN

NVDA

TSLA

XPEV

L&#39;era dei robot umanoidi è alle porte: quali società tecnologiche potrebbero beneficiare di questa trasformazione?

Il futuro è umanoide: le azioni su cui consiglia di puntare Morgan Stanley

Politics

Tech

RIVN

La revoca dell&#39;ordine esecutivo di Biden da parte di Trump scuote il mercato dei veicoli elettrici, favorendo le startup cinesi.

Trump revoca l&#39;ordine di Biden: volano le startup cinesi, crolla Rivian

Movers

Media

General

SMOG

Questo nuovo SUV elettrico promette di rivoluzionare il mercato, con caratteristiche avanzate e un design innovativo.

Nuova auto elettrica cinese in arrivo: ecco di chi si tratta

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

XPeng Inc

FCX currently expects its consolidated copper sales for first-quarter 2025 to be in line with its January 2025 guidance of 850 million pounds and its gold sales for first quarter 2025 to be approximately 100 thousand ounces below its January 2025 guidance of 225 thousand ounces.
FCX is reviewing its annual consolidated sales guidance in connection with its routine quarterly forecast updates and does not currently expect a material change to its 2025 annual guidance.
 &nbsp;
 &nbsp;

Guidance

Freeport Says Q1 Copper And Gold Production Approximated Expectations; Expects No Material Impact On Annual Consolidated Sales Guidance

<h3>Gainers</h3>
<ul>
<li>SharpLink Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) stock increased by 37.5% to $0.4 during Monday's after-market session. The company's market cap stands at $2.7 million. </li>
<li>Sportsman's Warehouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWH#NASDAQ">SPWH</a>) stock rose 15.68% to $1.15. The market value of their outstanding shares is at $43.6 million. </li>
<li>PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) stock moved upwards by 15.51% to $74.67. The market value of their outstanding shares is at $4.1 billion. The company's, Q4 earnings came out today. </li>
<li>Lazydays Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GORV#NASDAQ">GORV</a>) stock increased by 14.05% to $0.37. The company's market cap stands at $40.6 million. As per the press release, Q4 earnings came out today. </li>
<li>MKDWell Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) shares increased by 11.66% to $0.33. The market value of their outstanding shares is at $6.1 million. </li>
<li>Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) shares moved upwards by 10.66% to $0.19. The market value of their outstanding shares is at $10.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>LightInTheBox Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) stock declined by 14.5% to $1.71 during Monday's after-market session. The company's market cap stands at $190.0 million. The company's, Q4 earnings came out 4 days ago. </li>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) stock declined by 10.57% to $1.1. The market value of their outstanding shares is at $1.6 million. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares fell 9.51% to $1.9. The company's market cap stands at $511.8 million. </li>
<li>Color Star Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADD#NASDAQ">ADD</a>) shares declined by 6.77% to $0.66. </li>
<li>Mullen Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) stock fell 6.67% to $0.1. </li>
<li>Allurion Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) stock fell 6.24% to $3.01. The company's market cap stands at $17.9 million. As per the news, the Q4 earnings report came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALUR

CLEU

GORV

LITB

MKDW

MULN

SBET

SPWH

TRNR

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. </li>
<li>Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. </li>
<li>Plus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTV#NASDAQ">PSTV</a>) stock moved upwards by 17.7% to $1.13. The market value of their outstanding shares is at $6.6 million. The company's, Q4 earnings came out 2 days ago. </li>
<li>Bionano Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNGO#NASDAQ">BNGO</a>) stock moved upwards by 16.29% to $3.24. The market value of their outstanding shares is at $8.8 million. As per the press release, Q4 earnings came out today. </li>
<li>Talphera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLPH#NASDAQ">TLPH</a>) shares moved upwards by 10.48% to $0.55. The market value of their outstanding shares is at $9.3 million. The company's, Q4 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AquaBounty Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQB#NASDAQ">AQB</a>) stock fell 11.2% to $0.61 during Monday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Evoke Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVOK#NASDAQ">EVOK</a>) shares declined by 8.9% to $2.51. The company's market cap stands at $3.7 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 8.61% to $0.85. The market value of their outstanding shares is at $60.8 million. </li>
<li>Enzo Biochem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENZ#NYSE">ENZ</a>) stock declined by 7.83% to $0.34. The market value of their outstanding shares is at $17.8 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares decreased by 6.67% to $0.56. The market value of their outstanding shares is at $2.5 million. </li>
<li>Adverum Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADVM#NASDAQ">ADVM</a>) stock declined by 6.64% to $4.08. The market value of their outstanding shares is at $84.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADVM

BIAF

BNGO

CMPX

CTOR

EVOK

NUTX

PSTV

TLPH

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Microvast Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) shares rose 27.4% to $1.49 during Monday's after-market session. The company's market cap stands at $482.6 million. As per the press release, Q4 earnings came out today. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) stock moved upwards by 6.4% to $0.96. The company's market cap stands at $3.0 million. The company's, Q4 earnings came out today. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) shares increased by 5.17% to $0.44. The company's market cap stands at $20.7 million. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) stock rose 5.12% to $0.25. The company's market cap stands at $4.4 million. </li>
<li>Westwater Resources (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WWR#AMEX">WWR</a>) shares increased by 5.11% to $0.58. The company's market cap stands at $41.3 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares increased by 5.01% to $0.28. The market value of their outstanding shares is at $6.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>OneConstruction Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONEG#NASDAQ">ONEG</a>) stock decreased by 9.7% to $2.05 during Monday's after-market session. The market value of their outstanding shares is at $26.6 million. </li>
<li>Silynxcom (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SYNX#AMEX">SYNX</a>) stock declined by 8.84% to $3.3. The market value of their outstanding shares is at $17.6 million. </li>
<li>ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) shares decreased by 8.59% to $2.98. The company's market cap stands at $35.4 million. The company's, Q4 earnings came out today. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) stock decreased by 6.85% to $0.69. The market value of their outstanding shares is at $34.5 million. </li>
<li>Singularity Future Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGLY#NASDAQ">SGLY</a>) shares decreased by 5.88% to $0.72. The company's market cap stands at $3.0 million. </li>
<li>Greenland Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTEC#NASDAQ">GTEC</a>) shares decreased by 5.72% to $1.65. The company's market cap stands at $22.4 million. As per the press release, Q4 earnings came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGLC

ELPW

GTEC

MVST

ONEG

SGLY

SYNX

VCIG

WLGS

XPON

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) shares rose 36.3% to $6.05 during Monday's after-market session. The market value of their outstanding shares is at $93.5 million. </li>
<li>Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) shares moved upwards by 7.94% to $55.6. The company's market cap stands at $2.3 billion. As per the press release, Q1 earnings came out today. </li>
<li>MultiSensor AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) stock rose 7.33% to $1.0. The company's market cap stands at $32.0 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) stock moved upwards by 7.01% to $0.38. The market value of their outstanding shares is at $53.3 million. </li>
<li>GSI Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIT#NASDAQ">GSIT</a>) shares moved upwards by 6.4% to $2.16. The company's market cap stands at $55.2 million. </li>
<li>LivePerson (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPSN#NASDAQ">LPSN</a>) shares increased by 6.34% to $0.85. The market value of their outstanding shares is at $77.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cambium Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) stock fell 30.6% to $0.49 during Monday's after-market session. The company's market cap stands at $13.8 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) shares fell 17.84% to $0.52. The market value of their outstanding shares is at $5.5 million. </li>
<li>Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) stock decreased by 9.36% to $26.83. The market value of their outstanding shares is at $495.4 million. As per the press release, FY earnings came out today. </li>
<li>AmpliTech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPG#NASDAQ">AMPG</a>) shares decreased by 8.39% to $1.42. The company's market cap stands at $27.9 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock fell 5.67% to $2.83. The company's market cap stands at $1.5 million. </li>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) stock fell 5.4% to $0.66. The market value of their outstanding shares is at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMPG

CMBM

CSAI

GRRR

GSIT

INUV

LPSN

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

PRGS

SLNH

SVRE

12 Information Technology Stocks Moving In Monday's After-Market Session

Babcock &amp; Wilcox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) reported quarterly losses of $(0.52) per share which missed the analyst consensus estimate of $(0.01) by 5100 percent. The company reported quarterly sales of $200.80 million which missed the analyst consensus estimate of $213.07 million by 5.76 percent. This is a 11.62 percent decrease over sales of $227.20 million the same period last year.

Earnings

Earnings Misses

Babcock & Wilcox Q4 2024 GAAP EPS Continuing Operations $(0.52), Sales $200.80M

In the current session, Littelfuse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFUS#NASDAQ">LFUS</a>) is trading at $196.74, after a 2.10% drop. Over the past month, the stock decreased by 8.76%, and in the past year, by 16.31%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1743454881_0.png" alt="Past Year Chart" />

<h3>How Does Littelfuse P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Littelfuse has a better P/E ratio of 50.24 than the aggregate P/E ratio of 40.76 of the Electronic Equipment, Instruments &amp; Components industry. Ideally, one might believe that Littelfuse Inc. might perform better in the future than it's industry group, but it's probable that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1743454881_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

LFUS

Price Over Earnings Overview: Littelfuse

In the latest quarter, 8 analysts provided ratings for Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $34.25, a high estimate of $41.00, and a low estimate of $29.00. A decline of 8.37% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1743454868_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Halliburton among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$29.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Keith Mackey</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Kurt Hallead</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stephen Gengaro</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$37.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>David Anderson</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Lloyd Byrne</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$41.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Halliburton. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Halliburton compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Halliburton's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Halliburton's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Halliburton analyst ratings.</a>
<h2>Get to Know Halliburton Better</h2>
Halliburton Co is North America's largest oilfield service company as measured by market share. Despite industry fragmentation, it holds a leading position in the hydraulic fracturing and completions market, which makes up nearly half of its revenue. It also holds strong positions in other service offerings like drilling and completions fluids, which leverages its expertise in material science, as well as the directional drilling market. While we consider SLB the global leader in reservoir evaluation, we think Halliburton leads in any activity from the reservoir to the wellbore. The firm's innovations have helped multiple producers lower their development costs per barrel of oil equivalent, with techniques that have been homed in over a century of operations.
<h3>Halliburton: Financial Performance Dissected</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Negative Revenue Trend: Examining Halliburton's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -2.25% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.
Net Margin: Halliburton's net margin is impressive, surpassing industry averages. With a net margin of 10.96%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Halliburton's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.91% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Halliburton's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.42%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.82.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

8 Analysts Assess Halliburton: What You Need To Know

Across the recent three months, 8 analysts have shared their insights on T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated T. Rowe Price Group and provided 12-month price targets. The average target is $112.12, accompanied by a high estimate of $121.00 and a low estimate of $100.00. This current average has decreased by 4.89% from the previous average price target of $117.88. 
<img src="https://www.benzinga.com/files/images/story/2025/1743454853_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of T. Rowe Price Group among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chris Allen</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$100.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$121.00</td>
<td>$126.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$113.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$116.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$105.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$113.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$124.00</td>
</tr>
<tr>
<td>Aidan Hall</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$111.00</td>
<td>$116.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to T. Rowe Price Group. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of T. Rowe Price Group compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of T. Rowe Price Group's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of T. Rowe Price Group's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TROW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on T. Rowe Price Group analyst ratings.</a>
<h2>All You Need to Know About T. Rowe Price Group</h2>
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load us and international stock, hybrid, bond, and money market funds. At the end of October 2024, the firm had $1.607 trillion in managed assets, composed of equity (51%), balanced (34%), fixed-income and money market (12%), and alternative (3%) offerings. Approximately two thirds of managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a us-based asset manager, deriving less than 10% of its AUM from overseas.
<h3>T. Rowe Price Group: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: T. Rowe Price Group's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 11.11%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: T. Rowe Price Group's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 23.47%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 4.16%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.15%, the company showcases effective utilization of assets.
Debt Management: T. Rowe Price Group's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TROW

Expert Outlook: T. Rowe Price Group Through The Eyes Of 8 Analysts

13 analysts have shared their evaluations of Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Dynatrace and provided 12-month price targets. The average target is $63.31, accompanied by a high estimate of $69.00 and a low estimate of $57.00. Observing a 0.49% increase, the current average has risen from the previous average price target of $63.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1743454838_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Dynatrace by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$60.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$67.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$59.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thomas Blakey</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dynatrace. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dynatrace compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Dynatrace's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Dynatrace's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Dynatrace analyst ratings.</a>
<h2>Discovering Dynatrace: A Closer Look</h2>
Dynatrace is a cloud-native company that focuses on analyzing machine data. Its product portfolio, delivered as software as a service, allows a client to monitor and analyze its entire IT infrastructure. Dynatrace's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to use it for a variety of applications throughout their businesses.
<h3>Dynatrace: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Dynatrace's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 19.47%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Dynatrace's net margin is impressive, surpassing industry averages. With a net margin of 82.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dynatrace's ROE stands out, surpassing industry averages. With an impressive ROE of 15.4%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dynatrace's ROA excels beyond industry benchmarks, reaching 10.24%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.03.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Dynatrace Stock: Analyst Perspectives (13 Ratings)

In the preceding three months, 4 analysts have released ratings for Progyny (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGNY#NASDAQ">PGNY</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Progyny and provided 12-month price targets. The average target is $24.75, accompanied by a high estimate of $28.00 and a low estimate of $23.00. This current average reflects an increase of 35.02% from the previous average price target of $18.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1743454830_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Progyny by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Larsen</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$23.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Cherny</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Progyny. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Progyny compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Progyny's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Progyny's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PGNY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Progyny analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Progyny Better</h2>
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
<h3>Unraveling the Financial Story of Progyny</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Progyny's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 10.55% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Progyny's net margin excels beyond industry benchmarks, reaching 3.53%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Progyny's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.46% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.66%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.05, Progyny adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PGNY

Analyst Expectations For Progyny's Future

In the preceding three months, 24 analysts have released ratings for Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">13</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $521.17, a high estimate of $640.00, and a low estimate of $390.00. Observing a downward trend, the current average is 8.64% lower than the prior average price target of $570.46. 
<img src="https://www.benzinga.com/files/images/story/2025/1743454823_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Adobe is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thill</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$590.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$530.00</td>
<td>$530.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$410.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$430.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$540.00</td>
<td>$580.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$530.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$525.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$495.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$650.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$390.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$460.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$575.00</td>
<td>$620.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$528.00</td>
<td>$605.00</td>
</tr>
<tr>
<td>Rob Oliver</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$490.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Brian Schwartz</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$530.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$660.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$490.00</td>
<td>$551.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$550.00</td>
<td>$590.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$600.00</td>
<td>$640.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$515.00</td>
<td>$570.00</td>
</tr>
<tr>
<td>Matthew Swanson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$590.00</td>
<td>$590.00</td>
</tr>
<tr>
<td>Brad Zelnick</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$475.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$640.00</td>
<td>$700.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$475.00</td>
<td>$525.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Adobe. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Adobe compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Adobe's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ADBE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adobe analyst ratings.</a>
<h2>Unveiling the Story Behind Adobe</h2>
Adobe provides content creation, document management, and digital marketing and advertising software and services to creative professionals and marketers for creating, managing, delivering, measuring, optimizing, and engaging with compelling content multiple operating systems, devices, and media. The company operates with three segments: digital media content creation, digital experience for marketing solutions, and publishing for legacy products (less than 5% of revenue).
<h3>Key Indicators: Adobe's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Adobe's remarkable performance in 3 months is evident. As of 28 February, 2025, the company achieved an impressive revenue growth rate of 10.27%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Adobe's net margin is impressive, surpassing industry averages. With a net margin of 31.69%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Adobe's ROE stands out, surpassing industry averages. With an impressive ROE of 13.32%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Adobe's ROA stands out, surpassing industry averages. With an impressive ROA of 6.02%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.5, Adobe adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

Beyond The Numbers: 24 Analysts Discuss Adobe Stock

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) in the last three months.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $70.91, with a high estimate of $74.00 and a low estimate of $64.00. This upward trend is evident, with the current average reflecting a 2.92% increase from the previous average price target of $68.90.
<img src="https://www.benzinga.com/files/images/story/2025/1743454814_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Corteva among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bill Selesky</td>
<td>Argus Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$69.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$71.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$73.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$74.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$73.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$73.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$69.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Corteva. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Corteva compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Corteva's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Corteva analyst ratings.</a>
<h2>Unveiling the Story Behind Corteva</h2>
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
<h3>A Deep Dive into Corteva's Financials</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Corteva's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 7.31%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Materials sector.
Net Margin: Corteva's net margin is impressive, surpassing industry averages. With a net margin of -1.03%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Corteva's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.17%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Corteva's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.1%, the company showcases efficient use of assets and strong financial health.
Debt Management: Corteva's debt-to-equity ratio is below the industry average. With a ratio of 0.11, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CTVA

The Analyst Verdict: Corteva In The Eyes Of 11 Experts

For most of the past five years, bonds have been in a <a href="https://www.benzinga.com/markets/bonds">brutal bear market</a>. 
Since peaking on March 9, 2020, the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) — the world&#8217;s largest fixed-income ETF — has lost nearly 50%, battered by tight monetary policy, strong economic <a href="https://www.benzinga.com/topic/inflation">growth and persistent inflation.</a>
Yet, fresh reversal signals have started emerging as the first quarter of 2025 draws close.
The gauge tracking longer-dated Treasury securities jumped 4.2% in the first quarter. In contrast, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), a benchmark for U.S. stocks, fell 5% over the same period. 
That 9% performance gap favoring bonds over stocks is the largest in a single quarter since April 2020.
<h3 class="wp-block-heading">TLT Notched Strongest Outperformance Over S&amp;P 500 Since Q1 2020</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="529" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31162615/TLT_SPY_2025-03-31_21-25-44_b61eb-1024x529.png" alt="" class="wp-image-849965" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31162615/TLT_SPY_2025-03-31_21-25-44_b61eb-1024x529.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31162615/TLT_SPY_2025-03-31_21-25-44_b61eb-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31162615/TLT_SPY_2025-03-31_21-25-44_b61eb-768x396.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31162615/TLT_SPY_2025-03-31_21-25-44_b61eb-1536x793.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/31162615/TLT_SPY_2025-03-31_21-25-44_b61eb.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h3 class="wp-block-heading">Why Are Bonds Suddenly Back?</h3>
Kent Thune, a CFP and investment advisor for ETF.com, believes the answer may lie in the shifting consumer confidence. 
"Weren't bond prices supposed to fall amid the inflationary potential of tariffs, tax cuts and deportations? What explains TLT's unexpected performance? The short answer is consumer confidence," Thune said.
Indeed, consumer sentiment is deteriorating rapidly. This signals that households may begin to reduce spending. That&#8217;s a troubling sign for a U.S. economy where consumption accounts for 70% of gross domestic product.
The University of Michigan&#8217;s final consumer sentiment index for March dropped sharply to 57.0, down from 64.7 in February. This is the lowest reading since November 2022. 
"Consumer sentiment confirmed its early month reading and fell for the third straight month, plummeting 12% from February," said Joanne Hsu, director of the university's Surveys of Consumers.
This souring sentiment comes as longer-term inflation expectations—shaping behaviors like wage negotiations and mortgage demand—jumped to 4.1%, the highest since 1993.
According to the CME FedWatch tool, traders are pricing in a 75% chance that the Federal Reserve will cut rates by at least 25 basis points at its June meeting.
The Atlanta&#8217;s Fed GDPNow model estimates a 2.8% economic contraction for the year&#8217;s first quarter.
These signs of economic strain have driven investors toward bonds in a flight to safety, even as inflation concerns continue to cloud the outlook.
<h3 class="wp-block-heading">Not Everyone Is Buying The Recession Narrative</h3>
What if the U.S. economy avoids a recession altogether and remains resilient? After all, on Wall Street, not everyone seems rattled by soft consumer sentiment data or slowing GDP estimates.
Even Federal Reserve Chair Jerome Powell dismissed the <a href="https://www.benzinga.com/news/25/03/44344560/horrific-report-economists-warn-consumer-confidence-collapse-signals-economic-trouble">University of Michigan's sentiment survey</a> as an "outlier." 
Veteran strategist Ed Yardeni remains skeptical the Fed will cut rates anytime soon. 
"We've been predicting none-and-done for Fed rate-cutting this year because of better-than-expected GDP growth," Yardeni said. "Now we are predicting that the Fed won't be able to ease even if the economy stagnates because higher inflation will force the Fed to stay put. The Fed Put will remain on hold."
Yardeni expects the 10-year Treasury yield to stay anchored in the 4.25%-4.75% range. That would likely cap further upside for long-duration bonds. If yields remain flat—or rise—bond performance could turn negative again.
Bravos Research highlighted in an email that Treasury yields are back to where they were in late 2022, suggesting relative stability rather than turmoil. 
"Over the last few months, bond yields have been essentially flat, not reflecting major recession concerns from bond investors," the firm said.
That's a stark contrast from past recessions like 2008 and 2001, when yields plunged sharply in anticipation of economic pain. Today, the bond market is projecting calm, not crisis.
Labor market data supports that outlook. Total U.S. employment continues to grow steadily—an unusual pattern for a pre-recession environment. "The stock market's performance is generally tied to the strength of the job market," Bravos said. "A deterioration in employment would make us more worried about a significant correction in the S&amp;P 500, similar to 2001 and 2008. But we're not seeing evidence of that right now."
With no clear signs of labor weakness or financial stress, Bravos Research views the recent stock pullback not as a warning shot but as a tactical buying opportunity.
"Given we don't believe a recession will happen in 2025, we think by year-end this will have proven to be a buying opportunity," the firm said.
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/03/44563303/gold-beats-sp-500-by-widest-margin-since-2011-as-tariff-fears-trigger-rush-to-havens">Gold Beats S&amp;P 500 By Widest Margin Since 2011 As Tariff Fears Trigger Rush To Havens</a></li>
</ul>
Image: Shutterstock

Government

Regulations

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Treasuries

Federal Reserve

ETFs

iShares Trust Barclays 20+ Year Treasury Bond Fund

Treasury Bonds Have Lost 50% In 5 Years, Yet Reversal Signals Emerge In Q1: Could Tariffs Actually Push TLT Higher?

The plan includes an intention to wind down the EA equipment business in an effort to prioritize core semiconductor assembly business opportunities and enhance overall through-cycle financial performance.&nbsp;
As a result of this intended cessation of business, the Company expects to incur total pre-tax charges, including impairments, in the range of $86 million and $100 million.
&nbsp;

KLIC

On March 25, Kulicke And Soffa Board Approved Strategic Plan Related To Cessation Of Its Electronics Assembly Equipment Business; Expects Total Pre-tax Charges Of $86M - $100M -  Filing

The <a href="https://www.benzinga.com/topic/cannabis-industry">cannabis industry</a> is grappling with a wave of financial distress as multiple publicly traded companies defaulted on key real estate obligations this past week. Gold Flora (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRAM#OTC">GRAM</a>), 4Front Ventures (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) and TILT Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TLLTF#OTC">TLLTF</a>), three major players in the cannabis sector, were all declared in default on leases held by cannabis-focused real estate investment trust (REIT) Innovative Industrial Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>). The developments highlight the mounting pressure on operators navigating a capital-starved environment, high taxation and an oversaturated market.
<h3 class="wp-block-heading">Gold Flora's Collapse: A Long Time Coming</h3>
On March 27, 2025, Gold Flora filed for voluntary receivership. IIPR subsequently declared Gold Flora in default of three leases, with a total invested value of approximately $117 million and an embedded cost of around $254 per square foot.
Gold Flora's financial struggles were not unexpected. According to a recent <a href="https://dealtracker.viridianca.com/chart-of-the-week/">Viridian Capital Advisors</a> analysis, the company had been hovering around a 5x liabilities-to-market cap ratio since late 2022—an early warning sign of distress. It officially crossed the critical 10x threshold in October 2024, a point at which Viridian noted that companies typically spiral into deeper financial trouble. The company had also experienced successive downgrades in Viridian's Credit Ranking Model, further signaling deteriorating financial health.
<h3 class="wp-block-heading">4Front Ventures And TILT Holdings Face Lease Defaults</h3>
In addition to Gold Flora, 4Front Ventures and TILT Holdings were also declared in default by IIPR.
4Front's default includes four leases, notably impacting its flagship 250,000-square-foot facility in Matteson, Illinois. The company first breached the 10x liabilities-to-market cap threshold in November 2024 and has since soared past 20x, a level Viridian considers highly distressed.
Also read: <a href="https://www.benzinga.com/analyst-ratings/initiation/25/03/44521557/canopy-growths-future-hinges-on-us-cannabis-regulatory-shifts-says-analyst-issuing-neutral-rating">Canopy Growth&#8217;s Future Hinges On US Cannabis Regulatory Shifts, Says Analyst, Issuing &#8216;Neutral&#8217; Rating</a>
TILT Holdings, meanwhile, defaulted on two leases, including a 40,000-square-foot facility in Taunton, MA, and a 15,000-square-foot property in White Haven, PA. TILT has struggled with high leverage for years, remaining above 10x since 2022 with only brief dips between 8x and 10x. While insolvency does not necessarily trigger defaults, sustained distress and a lack of financial relief have pushed TILT to its breaking point.
<h3 class="wp-block-heading">Who's Next? Key Companies To Watch</h3>
Viridian's liabilities-to-market cap ratio is a crucial early warning indicator of financial distress. While defaults rarely occur without warning, some cannabis companies are approaching precarious levels of financial strain.
Cannabist Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBST#OTC">CBST</a>) surpassed 10x liabilities-to-market cap in November 2024 and has since ballooned to 32x. However, a recent debt exchange has given the company short-term breathing room, staving off an immediate default.
Ascend Wellness Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AAWH#OTC">AAWH</a>) crossed the 10x threshold in December 2024, remaining between 11 and 12x. Unlike Gold Flora or 4Front, Ascend has no major debt maturities until 2029, meaning its financial troubles are less likely to trigger immediate default.
AYR Wellness (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AYRWF#OTC">AYRWF</a>), on the other hand, presents a more urgent risk. The company has an upcoming debt maturity and lacks sufficient asset coverage, making it a potential candidate for default unless it secures a refinancing solution.
<h3 class="wp-block-heading">The Bigger Picture: A Capital Crunch Across The Industry</h3>
These defaults highlight a broader liquidity crisis in the cannabis industry, exacerbated by limited access to traditional banking, high operating costs and declining wholesale prices. While some companies manage to secure short-term lifelines through debt restructuring, others, like Gold Flora, cannot sustain operations.
For investors, the liabilities-to-market cap ratio remains a reliable distress indicator, offering insight into which companies are at risk of default. As the market continues to face financial headwinds, more cannabis operators may find themselves on precarious financial footing in the coming months.
Now Read:
<ul>
<li><a href="http://NYC Cannabis Czar Dasheeda Dawson Steps Down: What's Next?">NYC Cannabis Czar Dasheeda Dawson Steps Down: What&#8217;s Next?</a></li>
</ul>
View This Week&#8217;s <a href="https://viridianca.us1.list-manage.com/track/click?u=078ead34a8bbcfd77b0486326&amp;id=68e4bf5f28&amp;e=0cc7343e29" target="_blank" rel="noreferrer noopener">Viridian Chart of the Week</a>&nbsp;For More Analysis
Lead image via Shutterstock

Cannabis

AAWH

AYRWF

CBST

FFNTF

GRAM

IIPR

TLLTF

Cannabis Defaults Are Piling Up: 3 Companies Just Missed Payments—Who's At Risk Next?

CoreWeave Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) shares traded lower as investors react to the company's disappointing IPO performance and <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44566197/coreweave-ipo-performance-likely-due-to-company-not-ai-sector-analyst-says-investor-sentiment-remains-mixed">concerns about its financials. </a>
What To Know: Analysts point to several factors weighing on CoreWeave's stock. The company initially aimed to raise $2.7 billion but settled for $1.5 billion, with Nvidia stepping in to support the offering due to weaker-than-expected demand. CoreWeave generated $1.9 billion in revenue last year but remains unprofitable and carries $7 billion in debt, raising concerns about its valuation. 
The stock, which debuted Friday at $40 per share after pricing below the expected $47 to $55 range, has struggled to gain momentum despite backing from Nvidia.
Investor sentiment toward AI infrastructure stocks remains mixed, with Microsoft recently signaling a slowdown in its AI spending. Analysts say CoreWeave's struggles are more about company-specific risks rather than a broader weakness in the AI sector.
Despite the weak debut, CoreWeave has secured key partnerships, including a 15-year lease agreement with Galaxy Digital. Some analysts see potential for growth if the company can leverage its relationships with Nvidia, OpenAI and Microsoft to expand its high-performance computing services.
The stock continues to trade within a tight range of $36 to $41.94 since going public, with investors watching for signs of stability and improved financial performance.
CRWV Price Action: Coreweave closed down 7.30% at $37.08 at the time of writing, but was up slightly in after-hours trading, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44570070/tariffs-inflation-and-tumbling-markets-these-5-etfs-thrived-amid-the-chaos-last-week">Tariffs, Inflation And Tumbling Markets: These 5 ETFs Thrived Amid Last Week&#8217;s Chaos</a></li>
</ul>
Photo: Shutterstock.

CRWV

CoreWeave Shares Are Trading Lower Today: What's Going On?

If you&#8217;ve been paying attention to the stock market recently, you must have come across a rather unexpected turn of events—value stocks are taking center stage from their flashy growth rivals. Over the course of three months, the Russell 1000 Value Index has <a href="https://www.benzinga.com/general/market-summary/25/03/44555763/value-stocks-are-crushing-growth-superstars-in-2025-is-more-to-come">beaten the Russell 1000 Growth Index </a>by a healthy 11%. That&#8217;s a far cry from this time last year, when tech and AI plays were driving the market upwards.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/03/44569468/growth-or-value-allsprings-new-etfs-offer-both">Growth Or Value? Allspring&#8217;s New ETFs Offer Both</a>
With tariffs, geopolitical tensions, and recession jitters swirling, investors are flocking to the relative safety of value stocks. But is it a permanent pivot, or a temporary sidetrack? Although no one knows for sure what the market will do, history suggests that value stocks have a way of surviving rough patches.
For those looking to ride the wave, these <a href="https://www.benzinga.com/etfs">four value-based ETFs</a> are worth considering:
iShares Russell 1000 Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWD#NYSE">IWD</a>)
The first choice for most investors seeking to follow the Russell 1000 Value Index, IWD offers broad exposure to large-cap value stocks from a wide range of sectors, such as financials, healthcare, and consumer staples. Some of its holdings include stocks of JP Morgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>). With its size and liquidity, this ETF is a convenient means of achieving diversified exposure to the value sector. It carries an expense ratio of 0.19%.
Vanguard Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTV#NYSE">VTV</a>)
An affordable fund with a bottom-of-the-barrel expense ratio of 0.04%, VTV tracks the CRSP US Large Cap Value Index. Blue-chip stalwarts such as JPMorgan Chase, and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) are overweights in this fund, which is a good bet for stability and long-term growth.
SPDR S&amp;P 500 Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPYV#NYSE">SPYV</a>)
If you desire exposure to value stocks as part of the larger S&amp;P 500, SPYV may be considered. This ETF targets S&amp;P 500 stocks that reflect strong value features in terms of low price-to-earnings and price-to-book ratios. With the valuation differential between value and growth stocks as high as it is now, this ETF is poised to profit from a possible market correction. The portfolio is similar to that of IWD and VTV, and the expense ratio is 0.04%.
Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>)
Dividend stocks tend to overlap with value stocks, and SCHD is a good representative of this case. Concentrating on high-grade dividend-paying businesses, this ETF not only gets investors exposed to value stocks but also provides a steady income under market uncertainty. Its portfolio carries blue-chip brands such as Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). This ETF comes with an expense ratio of 0.06%.
Also Read: <a href="https://www.benzinga.com/25/03/44570070/tariffs-inflation-and-tumbling-markets-these-5-etfs-thrived-amid-the-chaos-last-week">Tariffs, Inflation And Tumbling Markets: These 5 ETFs Thrived Amid Last Week&#8217;s Chaos</a>
Why Value Could Stay On Top
Last quarter&#8217;s value outperformance is more than just jitters in the market. It&#8217;s because, as BlackRock&#8217;s Global CIO of Fundamental Equities Tony DeSpirito <a href="https://www.blackrock.com/us/individual/insights/value-stocks-underweight-and-unaware?utm_source=chatgpt.com">says</a>, growth stocks now comprise almost 40% of the S&amp;P 500—more than double their long-term average of 24%. With the valuations pulled forward, investors might begin shifting into value stocks for diversification. In addition, sectors like utilities, health care, and materials—staples in value indexes—are less tariff-vulnerable and potentially even positively affected by changes in trade policy.
While growth stocks may recover over time, the current market environment has favored value stocks. For those interested in exploring this trend, these four ETFs offer examples of funds that focus on value investing.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/03/44570028/westwoods-new-bfre-etf-prioritizes-democracy-over-autocracy">Westwood&#8217;s New BFRE ETF Prioritizes Democracy Over Autocracy</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

SCHD

SPYV

Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend

SIDU

Sidus Space FY24 Sales $4.67M Down From $5.96M YoY

This newly filed application seeks to expand the Company's intellectual property portfolio surrounding HT-001 and builds upon Hoth's already approved patent for the compound.

HOTH

Hoth Therapeutics Secures USPTO Filing Receipt For HT-001 Formulation Patent Application

Press Releases

XPENG Reports Third Quarter 2024 Unaudited Financial Results

SunCar Technology Group Inc. Joins the Prestigious NASDAQ Golden Dragon China Index

XPENG Announces Vehicle Delivery Results for November 2024

XPENG Announces Vehicle Delivery Results for December and Fourth Quarter 2024

XPENG and Volkswagen Group China to Jointly Build One of the Largest Super-Fast Charging Networks in China

XPENG selects RTI Connext Drive to Streamline Communication for its Next-Generation Vehicle Architecture

XPENG Announces Vehicle Delivery Results for January 2025

XPENG Announces Vehicle Delivery Results for February 2025

XPENG to Report Fourth Quarter and Fiscal Year 2024 Financial Results on Tuesday, March 18, 2025

XPENG Reports Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results

BABA

BIDU

Thunder Power Holdings, Inc. - Common Stock

Thunder Power Holdings

Cenntro

Chijet Motor Company, Inc. - Ordinary Shares

Chijet Motor Co

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Ford Motor

Faraday Future Intelligent Electric Inc. - Class A Common Stock

Faraday Future

Fly-E Group

General Motors

Honda Motor Co

Lucid Group

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Phoenix Motor

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Thor Industries

Toyota Motor

Tesla

VinFast Auto

Winnebago Industries

Workhorse Gr

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

XPeng

Notizie

Ultime notizie per XPeng (NYSE:XPEV) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO